189 related articles for article (PubMed ID: 10436086)
1. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies.
Atwell JL; Breheney KA; Lawrence LJ; McCoy AJ; Kortt AA; Hudson PJ
Protein Eng; 1999 Jul; 12(7):597-604. PubMed ID: 10436086
[TBL] [Abstract][Full Text] [Related]
2. ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers.
Dolezal O; Pearce LA; Lawrence LJ; McCoy AJ; Hudson PJ; Kortt AA
Protein Eng; 2000 Aug; 13(8):565-74. PubMed ID: 10964986
[TBL] [Abstract][Full Text] [Related]
3. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer.
Kortt AA; Lah M; Oddie GW; Gruen CL; Burns JE; Pearce LA; Atwell JL; McCoy AJ; Howlett GJ; Metzger DW; Webster RG; Hudson PJ
Protein Eng; 1997 Apr; 10(4):423-33. PubMed ID: 9194168
[TBL] [Abstract][Full Text] [Related]
4. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments.
Lawrence LJ; Kortt AA; Iliades P; Tulloch PA; Hudson PJ
FEBS Lett; 1998 Apr; 425(3):479-84. PubMed ID: 9563517
[TBL] [Abstract][Full Text] [Related]
5. [New type recombinant antibody fragment scFv multimer and cancer targeting].
Guo J; Cai M
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Jun; 20(2):361-5. PubMed ID: 12856620
[TBL] [Abstract][Full Text] [Related]
6. Triabodies: single chain Fv fragments without a linker form trivalent trimers.
Iliades P; Kortt AA; Hudson PJ
FEBS Lett; 1997 Jun; 409(3):437-41. PubMed ID: 9224705
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional structures of single-chain Fv-neuraminidase complexes.
Malby RL; McCoy AJ; Kortt AA; Hudson PJ; Colman PM
J Mol Biol; 1998 Jun; 279(4):901-10. PubMed ID: 9642070
[TBL] [Abstract][Full Text] [Related]
8. High avidity scFv multimers; diabodies and triabodies.
Hudson PJ; Kortt AA
J Immunol Methods; 1999 Dec; 231(1-2):177-89. PubMed ID: 10648937
[TBL] [Abstract][Full Text] [Related]
9. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex.
Kortt AA; Malby RL; Caldwell JB; Gruen LC; Ivancic N; Lawrence MC; Howlett GJ; Webster RG; Hudson PJ; Colman PM
Eur J Biochem; 1994 Apr; 221(1):151-7. PubMed ID: 8168505
[TBL] [Abstract][Full Text] [Related]
10. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.
Kortt AA; Dolezal O; Power BE; Hudson PJ
Biomol Eng; 2001 Oct; 18(3):95-108. PubMed ID: 11566601
[TBL] [Abstract][Full Text] [Related]
11. Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-0 (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium.
Dolezal O; De Gori R; Walter M; Doughty L; Hattarki M; Hudson PJ; Kortt AA
Protein Eng; 2003 Jan; 16(1):47-56. PubMed ID: 12646692
[TBL] [Abstract][Full Text] [Related]
12. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase.
Atwell JL; Pearce LA; Lah M; Gruen LC; Kortt AA; Hudson PJ
Mol Immunol; 1996 Dec; 33(17-18):1301-12. PubMed ID: 9171890
[TBL] [Abstract][Full Text] [Related]
13. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility.
Carmichael JA; Power BE; Garrett TP; Yazaki PJ; Shively JE; Raubischek AA; Wu AM; Hudson PJ
J Mol Biol; 2003 Feb; 326(2):341-51. PubMed ID: 12559905
[TBL] [Abstract][Full Text] [Related]
14. The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3.
Pei XY; Holliger P; Murzin AG; Williams RL
Proc Natl Acad Sci U S A; 1997 Sep; 94(18):9637-42. PubMed ID: 9275175
[TBL] [Abstract][Full Text] [Related]
15. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
16. Cyclization of Single-Chain Fv Antibodies Markedly Suppressed Their Characteristic Aggregation Mediated by Inter-Chain VH-VL Interactions.
Yamauchi S; Kobashigawa Y; Fukuda N; Teramoto M; Toyota Y; Liu C; Ikeguchi Y; Sato T; Sato Y; Kimura H; Masuda T; Ohtsuki S; Noi K; Ogura T; Morioka H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31323851
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment.
Arndt KM; Müller KM; Plückthun A
Biochemistry; 1998 Sep; 37(37):12918-26. PubMed ID: 9737871
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of a diabody, a bivalent antibody fragment.
Perisic O; Webb PA; Holliger P; Winter G; Williams RL
Structure; 1994 Dec; 2(12):1217-26. PubMed ID: 7704531
[TBL] [Abstract][Full Text] [Related]
19. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability.
Wörn A; Plückthun A
Biochemistry; 1998 Sep; 37(38):13120-7. PubMed ID: 9748318
[TBL] [Abstract][Full Text] [Related]
20. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
